{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:47:14Z","timestamp":1790948834804,"version":"4.1.0"},"reference-count":130,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Grundfos Foundation","award":["2020-025"],"award-info":[{"award-number":["2020-025"]}]},{"DOI":"10.13039\/501100001862","name":"The Swedish Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001862","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Union's Horizon 2020","award":["754936"],"award-info":[{"award-number":["754936"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"\n Background<\/jats:title>\n COVID-19 is a rapidly spreading disease that has caused extensive burden to individuals, families, countries, and the world. Effective treatments of COVID-19 are urgently needed. This is the second edition of a living systematic review of randomized clinical trials assessing the effects of all treatment interventions for participants in all age groups with COVID-19.<\/jats:p>\n <\/jats:sec>\n \n Methods and findings<\/jats:title>\n \n We planned to conduct aggregate data meta-analyses, trial sequential analyses, network meta-analysis, and individual patient data meta-analyses. Our systematic review was based on PRISMA and Cochrane guidelines, and our eight-step procedure for better validation of clinical significance of meta-analysis results. We performed both fixed-effect and random-effects meta-analyses. Primary outcomes were all-cause mortality and serious adverse events. Secondary outcomes were admission to intensive care, mechanical ventilation, renal replacement therapy, quality of life, and non-serious adverse events. According to the number of outcome comparisons, we adjusted our threshold for significance to\n p<\/jats:italic>\n = 0.033. We used GRADE to assess the certainty of evidence. We searched relevant databases and websites for published and unpublished trials until November 2, 2020. Two reviewers independently extracted data and assessed trial methodology. We included 82 randomized clinical trials enrolling a total of 40,249 participants. 81 out of 82 trials were at overall high risk of bias. Meta-analyses showed no evidence of a difference between corticosteroids versus control on all-cause mortality (risk ratio [RR] 0.89; 95% confidence interval [CI] 0.79 to 1.00;\n p<\/jats:italic>\n = 0.05; I\n 2<\/jats:sup>\n = 23.1%; eight trials; very low certainty), on serious adverse events (RR 0.89; 95% CI 0.80 to 0.99;\n p<\/jats:italic>\n = 0.04; I\n 2<\/jats:sup>\n = 39.1%; eight trials; very low certainty), and on mechanical ventilation (RR 0.86; 95% CI 0.55 to 1.33;\n p<\/jats:italic>\n = 0.49; I\n 2<\/jats:sup>\n = 55.3%; two trials; very low certainty). The fixed-effect meta-analyses showed indications of beneficial effects. Trial sequential analyses showed that the required information size for all three analyses was not reached. Meta-analysis (RR 0.93; 95% CI 0.82 to 1.07;\n p<\/jats:italic>\n = 0.31; I\n 2<\/jats:sup>\n = 0%; four trials; moderate certainty) and trial sequential analysis (boundary for futility crossed) showed that we could reject that remdesivir versus control reduced the risk of death by 20%. Meta-analysis (RR 0.82; 95% CI 0.68 to 1.00;\n p<\/jats:italic>\n = 0.05; I\n 2<\/jats:sup>\n = 38.9%; four trials; very low certainty) and trial sequential analysis (required information size not reached) showed no evidence of difference between remdesivir versus control on serious adverse events. Fixed-effect meta-analysis showed indications of a beneficial effect of remdesivir on serious adverse events. Meta-analysis (RR 0.40; 95% CI 0.19 to 0.87;\n p<\/jats:italic>\n = 0.02; I\n 2<\/jats:sup>\n = 0%; two trials; very low certainty) showed evidence of a beneficial effect of intravenous immunoglobulin versus control on all-cause mortality, but trial sequential analysis (required information size not reached) showed that the result was severely underpowered to confirm or reject realistic intervention effects. Meta-analysis (RR 0.63; 95% CI 0.35 to 1.14;\n p<\/jats:italic>\n = 0.12; I\n 2<\/jats:sup>\n = 77.4%; five trials; very low certainty) and trial sequential analysis (required information size not reached) showed no evidence of a difference between tocilizumab versus control on serious adverse events. Fixed-effect meta-analysis showed indications of a beneficial effect of tocilizumab on serious adverse events. Meta-analysis (RR 0.70; 95% CI 0.51 to 0.96;\n p<\/jats:italic>\n = 0.02; I\n 2<\/jats:sup>\n = 0%; three trials; very low certainty) showed evidence of a beneficial effect of tocilizumab versus control on mechanical ventilation, but trial sequential analysis (required information size not reached) showed that the result was severely underpowered to confirm of reject realistic intervention effects. Meta-analysis (RR 0.32; 95% CI 0.15 to 0.69;\n p<\/jats:italic>\n < 0.00; I\n 2<\/jats:sup>\n = 0%; two trials; very low certainty) showed evidence of a beneficial effect of bromhexine versus standard care on non-serious adverse events, but trial sequential analysis (required information size not reached) showed that the result was severely underpowered to confirm or reject realistic intervention effects. Meta-analyses and trial sequential analyses (boundary for futility crossed) showed that we could reject that hydroxychloroquine versus control reduced the risk of death and serious adverse events by 20%. Meta-analyses and trial sequential analyses (boundary for futility crossed) showed that we could reject that lopinavir-ritonavir versus control reduced the risk of death, serious adverse events, and mechanical ventilation by 20%. All remaining outcome comparisons showed that we did not have enough information to confirm or reject realistic intervention effects. Nine single trials showed statistically significant results on our outcomes, but were underpowered to confirm or reject realistic intervention effects. Due to lack of data, it was not relevant to perform network meta-analysis or possible to perform individual patient data meta-analyses.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n No evidence-based treatment for COVID-19 currently exists. Very low certainty evidence indicates that corticosteroids might reduce the risk of death, serious adverse events, and mechanical ventilation; that remdesivir might reduce the risk of serious adverse events; that intravenous immunoglobin might reduce the risk of death and serious adverse events; that tocilizumab might reduce the risk of serious adverse events and mechanical ventilation; and that bromhexine might reduce the risk of non-serious adverse events. More trials with low risks of bias and random errors are urgently needed. This review will continuously inform best practice in treatment and clinical research of COVID-19.<\/jats:p>\n <\/jats:sec>\n \n Systematic review registration<\/jats:title>\n \n PROSPERO\n CRD42020178787<\/jats:ext-link>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1371\/journal.pone.0248132","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T13:41:33Z","timestamp":1615470093000},"page":"e0248132","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":47,"title":["Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6171-2904","authenticated-orcid":true,"given":"Sophie","family":"Juul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil Eik","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Kamp","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Barot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Holgersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bentzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areti Angeliki","family":"Veroniki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lehana","family":"Thabane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanlong","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Klingenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8861-0799","authenticated-orcid":true,"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janus Christian","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"issue":"18","key":"pone.0248132.ref001","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China.","volume":"382","author":"W Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0248132.ref002","unstructured":"World Health Organization. Novel Coronavirus (2019-nCOV). Situation Report 51. 2020 [Available from: https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/situation-reports\/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10]"},{"key":"pone.0248132.ref003","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"B Cao","year":"2020","journal-title":"N Engl J Med"},{"issue":"10223","key":"pone.0248132.ref004","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.","volume":"395","author":"C Huang","year":"2020","journal-title":"Lancet."},{"issue":"10223","key":"pone.0248132.ref005","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","article-title":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.","volume":"395","author":"JF Chan","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"pone.0248132.ref006","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Z Xu","year":"2020","journal-title":"Lancet Respir Med."},{"key":"pone.0248132.ref007","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMe2002387","article-title":"Covid-19\u2014navigating the uncharted","volume":"382","author":"AS Fauci","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0248132.ref008","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13643-020-01371-0","article-title":"Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project).","volume":"9","author":"S Juul","year":"2020","journal-title":"Syst Rev."},{"issue":"7","key":"pone.0248132.ref009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"6","author":"D Moher","year":"2009","journal-title":"PLOS Med"},{"key":"pone.0248132.ref010","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"339","author":"A Liberati","year":"2009","journal-title":"BMJ"},{"key":"pone.0248132.ref011","article-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019).","author":"J Higgins","year":"2019","journal-title":"Cochrane"},{"key":"pone.0248132.ref012","unstructured":"The Cochrane Collaboration. Cochrane COVID-19 Study Register. Available at: https:\/\/covid-19.cochrane.org\/: [Accessed November 2, 2020]"},{"issue":"6","key":"pone.0248132.ref013","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1016\/S2589-7500(20)30086-8","article-title":"A real-time dashboard of clinical trials for COVID-19","volume":"2","author":"K Thorlund","year":"2020","journal-title":"Lancet Dig Health."},{"key":"pone.0248132.ref014","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"JA Sterne","year":"2019","journal-title":"BMJ"},{"key":"pone.0248132.ref015","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Guideline: Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice (ICH-GCP). 2015. Available from: https:\/\/ichgcp.net\/ [Accessed November 4, 2020]"},{"issue":"1","key":"pone.0248132.ref016","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-2288-10-90","article-title":"Evidence at a glance: error matrix approach for overviewing available evidence","volume":"10","author":"F Keus","year":"2010","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"pone.0248132.ref017","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1471-2288-14-120","article-title":"Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods.","volume":"14","author":"JC Jakobsen","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"pone.0248132.ref018","unstructured":"Review Manager (RevMan). Version 5.4. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2020. Available at: https:\/\/training.cochrane.org\/online-learning\/core-software-cochrane-reviews\/revman [Accessed November 10, 2020]"},{"key":"pone.0248132.ref019","volume-title":"Stata Statistical Software: Release 16","author":"StataCorp","year":"2019"},{"key":"pone.0248132.ref020","article-title":"Cochrane Handbook for Systematic Reviews of Interventions.","author":"J Higgins","year":"2011","journal-title":"The Cochrane Collaboration."},{"issue":"1","key":"pone.0248132.ref021","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/ije\/31.1.96","article-title":"Being sceptical about meta-analyses: a Bayesian perspective on magnesium trials in myocardial infarction.","volume":"31","author":"JP Higgins","year":"2002","journal-title":"Int J Epidemiol"},{"key":"pone.0248132.ref022","unstructured":"Copenhagen Trial Unit. TSA\u2014Trial Sequential Analysis. Available at: http:\/\/www.ctu.dk\/tsa\/ [Accessed November 2, 2020]"},{"issue":"1","key":"pone.0248132.ref023","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis.","volume":"61","author":"J Wetterslev","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"pone.0248132.ref024","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","article-title":"Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses.","volume":"61","author":"J Brok","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"pone.0248132.ref025","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/ije\/dyn188","article-title":"Apparently conclusive meta-analyses may be inconclusive\u2014trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses.","volume":"38","author":"J Brok","year":"2008","journal-title":"Int J Epidemiol"},{"issue":"1","key":"pone.0248132.ref026","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/ije\/dyn179","article-title":"Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?","volume":"38","author":"K Thorlund","year":"2008","journal-title":"Int J Epidemiol"},{"issue":"1","key":"pone.0248132.ref027","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating required information size by quantifying diversity in random-effects model meta-analyses.","volume":"9","author":"J Wetterslev","year":"2009","journal-title":"BMC Med Res Methodol"},{"key":"pone.0248132.ref028","author":"K Thorlund","year":"2011","journal-title":"User manual for trial sequential analysis (TSA)."},{"key":"pone.0248132.ref029","first-page":"57","article-title":"Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals","volume":"2","author":"K Thorlund","year":"2010","journal-title":"Clin Epidemiol"},{"issue":"8","key":"pone.0248132.ref030","doi-asserted-by":"crossref","first-page":"e011890","DOI":"10.1136\/bmjopen-2016-011890","article-title":"False-positive findings in Cochrane meta-analyses with and without application of trial sequential analysis: an empirical review","volume":"6","author":"G Imberger","year":"2016","journal-title":"BMJ Open"},{"key":"pone.0248132.ref031","article-title":"Remdesivir for the treatment of Covid-19\u2014Preliminary report","author":"JH Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0248132.ref032","first-page":"2020","article-title":"Favipiravir versus arbidol for COVID-19: A randomized clinical trial.","author":"C Chen","year":"2020","journal-title":"medRxiv"},{"issue":"1","key":"pone.0248132.ref033","article-title":"A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19).","volume":"49","author":"J Chen","year":"2020","journal-title":"J Zhejiang Univ (Med Sci)."},{"key":"pone.0248132.ref034","first-page":"2020","article-title":"Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial.","author":"Z Chen","year":"2020","journal-title":"medRxiv"},{"key":"pone.0248132.ref035","article-title":"Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: a randomized clinical trial.","author":"E Davoudi-Monfared","year":"2020","journal-title":"medRxiv."},{"key":"pone.0248132.ref036","article-title":"Remdesivir for 5 or 10 days in patients with severe Covid-19","author":"JD Goldman","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0248132.ref037","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"IF-N Hung","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"pone.0248132.ref038","first-page":"1","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial","volume":"324","author":"L Li","year":"2020","journal-title":"JAMA"},{"key":"pone.0248132.ref039","article-title":"Efficacy and safety of lopinavir\/ritonavir or arbidol in adult patients with mild\/moderate COVID-19: an exploratory randomized controlled trial","author":"Y Li","year":"2020","journal-title":"Cell Press"},{"key":"pone.0248132.ref040","article-title":"Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial.","author":"Y Lou","year":"2020","journal-title":"medRxiv"},{"key":"pone.0248132.ref041","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1136\/bmj.m1849","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.","volume":"369","author":"W Tang","year":"2020","journal-title":"BMJ"},{"issue":"10236","key":"pone.0248132.ref042","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Y Wang","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"pone.0248132.ref043","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/j.bja.2020.02.020","article-title":"High-flow nasal-oxygenation-assisted fibreoptic tracheal intubation in critically ill patients with COVID-19 pneumonia: a prospective randomised controlled trial","volume":"125","author":"CN Wu","year":"2020","journal-title":"Br J Anaesth"},{"key":"pone.0248132.ref044","article-title":"A novel protein drug, novaferon, as the potential antiviral drug for COVID-19.","author":"F Zheng","year":"2020","journal-title":"medRxiv"},{"key":"pone.0248132.ref045","article-title":"A randomized, single-blind, group sequential, active-controlled study to evaluate the clinical efficacy and safety of \u03b1-Lipoic acid for critically ill patients with coronavirus disease 2019 (COVID-19).","author":"M Zhong","year":"2020","journal-title":"medRxiv"},{"key":"pone.0248132.ref046","article-title":"Effect of dexamethasone in hospitalized patients with COVID-19 \u2013preliminary report.","author":"P Horby","year":"2020","journal-title":"medRxiv"},{"key":"pone.0248132.ref047","article-title":"Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study.","author":"L Chen","year":"2020","journal-title":"medRxiv."},{"issue":"6","key":"pone.0248132.ref048","doi-asserted-by":"crossref","first-page":"e2013136","DOI":"10.1001\/jamanetworkopen.2020.13136","article-title":"Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial.","volume":"3","author":"SG Deftereos","year":"2020","journal-title":"JAMA Netw Open."},{"issue":"4","key":"pone.0248132.ref049","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.","volume":"3","author":"MGS Borba","year":"2020","journal-title":"JAMA Netw Open"},{"key":"pone.0248132.ref050","article-title":"Convalescent plasma for COVID-19: a randomized clinical trial.","author":"A Gharbharan","year":"2020","journal-title":"medrRxiv"},{"key":"pone.0248132.ref051","article-title":"Dexamethasone in hospitalized patients with COVID-19\u2014preliminary report.","author":"RECOVERY Collaborative Group","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0248132.ref052","article-title":"Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial","author":"CP Skipper","year":"2020","journal-title":"Ann Intern Med"},{"key":"pone.0248132.ref053","article-title":"Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19","author":"AB Cavalcanti","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0248132.ref054","article-title":"Hydroxychloroquine for early treatment of adults with mild covid-19: a randomized-controlled trial","author":"O Mitj\u00e0","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pone.0248132.ref055","article-title":"GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia.","author":"L Corral-Gudino","year":"2020","journal-title":"medRxiv."},{"key":"pone.0248132.ref056","article-title":"Intravenous Immunoglobulin (IVIG) significantly reduces respiratory morbidity in COVID-19 pneumonia: a prospective randomized trial.","author":"G Sakoulas","year":"2020","journal-title":"medRxiv."},{"key":"pone.0248132.ref057","article-title":"Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: preliminary results from a multi-centre, randomized, controlled trial.","author":"P Horby","year":"2020","journal-title":"medRxiv"},{"key":"pone.0248132.ref058","article-title":"A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19).","author":"C-P Chen","year":"2020","journal-title":"medRxiv"},{"issue":"7","key":"pone.0248132.ref059","doi-asserted-by":"crossref","first-page":"ofaa241","DOI":"10.1093\/ofid\/ofaa241","article-title":"Antiviral activity and safety of darunavir\/cobicistat for the treatment of COVID-19.","volume":"7","author":"J Chen","year":"2020","journal-title":"Open Forum Infect Dis."},{"key":"pone.0248132.ref060","article-title":"Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir\/ritonavir plus interferon-alpha and ribavirin plus lopinavir\/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus pneumonia: results of a randomized, open-labeled prospective study.","author":"Y-K Chen","year":"2020","journal-title":"SSRN"},{"issue":"SP1)","key":"pone.0248132.ref061","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.15586\/jptcp.v27iSP1.684","article-title":"The comparison of the effectiveness of lincocin\u00ae and azitro\u00ae in the treatment of covid-19-associated pneumonia: A prospective study","volume":"27","author":"O Guvenmez","year":"2020","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"pone.0248132.ref062","article-title":"Pulmonary radiological change of COVID-19 patients with 99mTc-MDP treatment.","author":"X Yuan","year":"2020","journal-title":"medRxiv."},{"key":"pone.0248132.ref063","article-title":"Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial.","author":"E-M Idelsis","year":"2020","journal-title":"medRxiv"},{"key":"pone.0248132.ref064","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19\u2014final report.","volume":"383","author":"JH Beigel","year":"2020","journal-title":"N Eng J Med"},{"key":"pone.0248132.ref065","first-page":"2020","article-title":"Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.","author":"M Duarte","year":"2020","journal-title":"medRxiv"},{"key":"pone.0248132.ref066","first-page":"2020","article-title":"AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II\/III multicenter randomized clinical trial.","author":"AA Ivashchenko","year":"2020","journal-title":"medRxiv"},{"key":"pone.0248132.ref067","article-title":"Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (METCOVID): a randomised, double-blind, phase IIb, placebo-controlled trial.","author":"CMP Jeronimo","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pone.0248132.ref068","first-page":"2020","article-title":"Aprepitant as a combinant with dexamethasone reduces the inflammation via neurokinin 1 receptor antagonism in severe to critical COVID-19 patients and potentiates respiratory recovery: a novel therapeutic approach.","author":"R Mehboob","year":"2020","journal-title":"medRxiv"},{"key":"pone.0248132.ref069","article-title":"Anti-C5a Antibody (IFX-1) Treatment of severe COVID-19: An exploratory phase 2 randomized controlled trial.","author":"AP Vlaar","year":"2020","journal-title":"SSRN."},{"key":"pone.0248132.ref070","article-title":"Pulmonary rehabilitation in post-acute period of COVID-19 infection: prospective randomized controleld trial.","author":"T Duymaz","year":"2020","journal-title":"SSRN."},{"key":"pone.0248132.ref071","first-page":"2020","article-title":"Pharmacological inhibition of the kinin-kallikrein system in severe COVID-19: a proof-of-concept study.","author":"E Mansour","year":"2020","journal-title":"medRxiv"},{"issue":"19","key":"pone.0248132.ref072","article-title":"A randomized, open-label, controlled clinical trial of azvudine tablets in the treatment of mild and common COVID-19, a pilot study.","volume":"7","author":"Z Ren","year":"2020","journal-title":"Adv Sci."},{"issue":"1","key":"pone.0248132.ref073","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s13054-020-03220-x","article-title":"Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial.","volume":"24","author":"J Miller","year":"2020","journal-title":"Crit Care."},{"issue":"1","key":"pone.0248132.ref074","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s13287-020-01875-5","article-title":"Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells","volume":"11","author":"L Shu","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"pone.0248132.ref075","article-title":"High-dose vitamin C infusion for the treatment of critically ill COVID-19.","author":"J Zhang","year":"2020","journal-title":"Research Square."},{"issue":"4","key":"pone.0248132.ref076","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.4269\/ajtmh.20-0873","article-title":"Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study","volume":"103","author":"S Abd-Elsalam","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"pone.0248132.ref077","first-page":"2020","article-title":"Convalescent plasma for COVID-19: A multicenter, randomized clinical trial.","author":"C Avendano-Sola","year":"2020","journal-title":"medRxiv"},{"key":"pone.0248132.ref078","article-title":"Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial","author":"H Abbaspour Kasgari","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"pone.0248132.ref079","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkaa334","article-title":"Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial.","volume":"75","author":"A Sadeghi","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"pone.0248132.ref080","doi-asserted-by":"crossref","first-page":"106903","DOI":"10.1016\/j.intimp.2020.106903","article-title":"Interferon \u03b2-1b in treatment of severe COVID-19: a randomized clinical trial","volume":"88","author":"H Rahmani","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"pone.0248132.ref081","first-page":"106143","article-title":"Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomised trial.","volume":"2020","author":"E Sekhavati","journal-title":"Int J Antimicrob Agents"},{"key":"pone.0248132.ref082","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(20)31862-6","article-title":"Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.","volume":"396","author":"RHM Furtado","year":"2020","journal-title":"Lancet"},{"key":"pone.0248132.ref083","article-title":"Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study","author":"ME Castillo","year":"2020","journal-title":"J Steroid Biochem Mol Biol"},{"key":"pone.0248132.ref084","article-title":"Effect of recombinant human granulocyte colony\u2013stimulating factor for patients with coronavirus disease 2019 (COVID-19) and lymphopenia: a randomized clinical trial.","author":"L-l Cheng","year":"2020","journal-title":"JAMA Intern med"},{"issue":"11","key":"pone.0248132.ref085","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"CD Spinner","year":"2020","journal-title":"JAMA"},{"key":"pone.0248132.ref086","article-title":"Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial","author":"BM Tomazini","year":"2020","journal-title":"JAMA"},{"issue":"13","key":"pone.0248132.ref087","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/jama.2020.16761","article-title":"Effect of hydrocortisone on 21-Day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial","volume":"324","author":"P-F Dequin","year":"2020","journal-title":"JAMA"},{"issue":"13","key":"pone.0248132.ref088","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.2020.17022","article-title":"Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial.","volume":"324","author":"The Writing Committee for the REMAP-CAP Investigators","year":"2020","journal-title":"JAMA"},{"key":"pone.0248132.ref089","article-title":"Tocilizumab in hospitalized patients with COVID-19 pneumonia.","author":"I Rosas","year":"2020","journal-title":"medRxiv."},{"key":"pone.0248132.ref090","article-title":"Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial).","author":"A Agarwal","year":"2020","journal-title":"medRxiv"},{"key":"pone.0248132.ref091","article-title":"Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial.","author":"MIF Lopes","year":"2020","journal-title":"medRxiv"},{"key":"pone.0248132.ref092","article-title":"Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial.","author":"D Wang","year":"2020","journal-title":"SSRN"},{"key":"pone.0248132.ref093","article-title":"Bromhexine hydrochloride tablets for the treatment of moderate COVID-19: an open-label randomized controlled pilot study.","author":"T Li","year":"2020","journal-title":"Clin Transl Sci."},{"key":"pone.0248132.ref094","article-title":"The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomised placebo-controlled double-blind clinical trial.","author":"N Gharebaghi","year":"2020","journal-title":"Research Square."},{"key":"pone.0248132.ref095","article-title":"Evaluation of the efficacy of methylprednisolone pulse therapy in treatment of covid-19 adult patients with severe respiratory failure: randomized, clinical trial.","author":"RH Farahani","year":"2020","journal-title":"Research Square."},{"key":"pone.0248132.ref096","unstructured":"ClinicalTrials.gov National Library of Medicine (US). Identifier NCT04244591: Glucocorticoid therapy for COVID-19 critically ill patients with severe acute respiratory failure Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT042445912020 [Accessed November 2, 2020)"},{"key":"pone.0248132.ref097","article-title":"Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial.","author":"M Edalatifard","year":"2020","journal-title":"Eur Res J."},{"key":"pone.0248132.ref098","unstructured":"ClinicalTrials.gov National Library of Medicine (US). Identifier NCT04325061: Efficacy of dexamethasone treatment for patients with ARDS caused by COVID-19 (DEXA-COVID19) Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT043250612020 [Accessed November 2, 2020]"},{"key":"pone.0248132.ref099","article-title":"Patient-reported health outcomes after treatment of COVID-19 with nebulized and\/or intravenous neutral electrolyzed saline combined with usual medical care versus usual medical care alone: a randomized, open-label, controlled trial.","author":"I Delgado-Enciso","journal-title":"Research Square."},{"key":"pone.0248132.ref100","article-title":"Interim analysis of an open-label randomized controlled trial evaluating nasal irrigations in non-hospitalized patients with COVID-19","author":"KS Kimura","year":"2020","journal-title":"Int Forum Allergy Rhinol"},{"key":"pone.0248132.ref101","article-title":"Efficacy and safety of triazavirin therapy for coronavirus disease 2019: a pilot randomized controlled trial.","author":"X Wu","year":"2020","journal-title":"Engineering"},{"key":"pone.0248132.ref102","article-title":"Double-blind, randomized, placebo-controlled trial with N-acetylcysteine for treatment of severe acute respiratory syndrome caused by COVID-19","author":"JCG de Alencar","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pone.0248132.ref103","doi-asserted-by":"crossref","first-page":"209","DOI":"10.34172\/bi.2020.27","article-title":"Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: a randomized clinical trial.","volume":"10","author":"K Ansarin","year":"2020","journal-title":"BioImpacts"},{"key":"pone.0248132.ref104","article-title":"A pragmatic randomized controlled trial reports the efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics.","author":"MN Lyngbakken","year":"2020","journal-title":"Research Square."},{"key":"pone.0248132.ref105","article-title":"Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.","author":"PW Horby","year":"2020","journal-title":"Lancet"},{"key":"pone.0248132.ref106","article-title":"The impact of colchicine on the COVID-19 patients: a clinical trial study.","author":"F Salehzadeh","year":"2020","journal-title":"Research Square"},{"key":"pone.0248132.ref107","article-title":"Treating COVID-19 with hydroxychloroquine (TEACH): a multicenter, double-blind, randomized controlled trial in hospitalized patients.","author":"RJ Ulrich","year":"2020","journal-title":"Open Forum Infect Dis."},{"key":"pone.0248132.ref108","article-title":"Effect of arbidol on COVID-19: a randomized controlled trial.","author":"M Nojomi","year":"2020","journal-title":"Research Square."},{"key":"pone.0248132.ref109","article-title":"Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results.","author":"H Pan","year":"2020","journal-title":"medRxiv."},{"key":"pone.0248132.ref110","article-title":"Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial","author":"O Hermine","year":"2020","journal-title":"JAMA Intern Med"},{"key":"pone.0248132.ref111","article-title":"Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial","author":"C Salvarani","year":"2020","journal-title":"JAMA Intern Med"},{"key":"pone.0248132.ref112","article-title":"Efficacy of tocilizumab in patients hospitalized with COVID-19.","author":"JH Stone","year":"2020","journal-title":"N Eng J Med"},{"key":"pone.0248132.ref113","article-title":"Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size","author":"H Zhao","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"pone.0248132.ref114","article-title":"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.","author":"Y Cao","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"pone.0248132.ref115","first-page":"e13600","article-title":"Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial.","volume":"2020","author":"L Davoodi","journal-title":"Int J Clin Pract"},{"key":"pone.0248132.ref116","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","author":"JA Sterne","year":"2020","journal-title":"JAMA"},{"key":"pone.0248132.ref117","doi-asserted-by":"crossref","first-page":"m2980","DOI":"10.1136\/bmj.m2980","article-title":"Drug treatments for covid-19: living systematic review and network meta-analysis","volume":"370","author":"RA Siemieniuk","year":"2020","journal-title":"BMJ"},{"issue":"9","key":"pone.0248132.ref118","doi-asserted-by":"crossref","first-page":"e1003293","DOI":"10.1371\/journal.pmed.1003293","article-title":"Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project).","volume":"17","author":"S Juul","year":"2020","journal-title":"PLOS Med."},{"key":"pone.0248132.ref119","unstructured":"U.S. Food and Drug Administration (FDA) News Release, FDA approves first treatment for COVID-19 [press release]. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19 [Accessed October 23, 2020]"},{"key":"pone.0248132.ref120","article-title":"Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.","author":"C Axfors","year":"2020","journal-title":"medRxiv."},{"key":"pone.0248132.ref121","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejim.2016.03.020","article-title":"Evidence-based clinical practice: Overview of threats to the validity of evidence and how to minimise them","volume":"32","author":"S Garattini","year":"2016","journal-title":"Eur J Intern Med"},{"issue":"6","key":"pone.0248132.ref122","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/aje\/kwj069","article-title":"Bias in clinical intervention research","volume":"163","author":"LL Gluud","year":"2006","journal-title":"Am J Epidemiol"},{"issue":"11","key":"pone.0248132.ref123","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"LL Kjaergard","year":"2001","journal-title":"Ann Intern Med"},{"issue":"7303","key":"pone.0248132.ref124","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Assessing the quality of controlled clinical trials","volume":"323","author":"P J\u00fcni","year":"2001","journal-title":"BMJ"},{"issue":"9128","key":"pone.0248132.ref125","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"D Moher","year":"1998","journal-title":"Lancet"},{"issue":"5","key":"pone.0248132.ref126","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"KF Schulz","year":"1995","journal-title":"JAMA"},{"issue":"4","key":"pone.0248132.ref127","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/ije\/dyu115","article-title":"Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies.","volume":"43","author":"A Hrobjartsson","year":"2014","journal-title":"Int J Epidemiol."},{"issue":"4","key":"pone.0248132.ref128","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.120744","article-title":"Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors.","volume":"185","author":"A Hrobjartsson","year":"2013","journal-title":"CMAJ"},{"key":"pone.0248132.ref129","doi-asserted-by":"crossref","first-page":"e1119","DOI":"10.1136\/bmj.e1119","article-title":"Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors","volume":"344","author":"A Hrobjartsson","year":"2012","journal-title":"BMJ"},{"key":"pone.0248132.ref130","unstructured":"The Cochrane Collaboration. Living mapping and living systematic review of Covid-19 studies. Available at: www.covid-nma.com [Accessed November 2, 2020]"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0248132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:51:27Z","timestamp":1671583887000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0248132"}},"subtitle":[],"editor":[{"given":"Stefanos","family":"Bonovas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":130,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0248132","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.11.22.20236448","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,11]]}}}